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Abstract
Presenilin1 (PS1) is a component of the c-secretase complex mutated in cases of Familial Alzheimer’s disease (FAD). PS1 is
synthesized as a 50 kDa peptide subsequently processed to two 29 and 20 kDa subunits that remain associated. Processing
of PS1 is inhibited by several mutations detected in FAD patients. PS1 acts as negative modulator of b-catenin?Tcf-4
transcriptional activity. In this article we show that in murine embryonic fibroblasts (MEFs) the mechanisms of action of the
processed and non-processed forms of PS1 on b-catenin?Tcf-4 transcription are different. Whereas non-processed PS1
inhibits b-catenin?Tcf-4 activity through a mechanism independent of c-secretase and associated with the interaction of this
protein with plakoglobin and Tcf-4, the effect of processed PS1 is prevented by c-secretase inhibitors, and requires its
interaction with E- or N-cadherin and the generation of cytosolic terminal fragments of these two cadherins, which in turn
destabilize the b-catenin transcriptional cofactor CBP. Accordingly, the two forms of PS1 interact differently with E-cadherin
or b-catenin and plakoglobin: whereas processed PS1 binds E-cadherin with high affinity and b-catenin or plakoglobin
weakly, the non-processed form behaves inversely. Moreover, contrarily to processed PS1, that decreases the levels of c-fos
RNA, non-processed PS1 inhibits the expression c-myc, a known target of b-catenin?Tcf-4, and does not block the activity of
other transcriptional factors requiring CBP. These results indicate that prevention of PS1 processing in FAD affects the
mechanism of repression of the transcriptional activity dependent on b-catenin.
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Introduction
Presenilin 1 (PS1) encodes a ubiquitously expressed, eight-
transmembrane protein involved in most cases of early-onset
Familial Alzheimer’s disease (FAD) [1,2]. PS1 is synthesized as a
50 kDa polypeptide that is subject to endoproteolytic cleavage to
generate stable N- and C-terminal derivatives of 29 and 20 kDa,
respectively, which form the active 1:1 heterodimer [3]. As well as
in ER and Golgi compartments, PS1 is located at the plasma
membrane where it directly binds to the cadherin/catenin
complexes [4–6].
PS1 assembleswith nicastrin,aph-1andpen-2 toformthelarge c-
secretase complex, responsible for the cleavage of several type-I
transmembrane proteins, including the b-amyloid precursor protein
(APP), Notch, CD44, ErbB4, E-cadherin and N-cadherin [5,7–12],
among others. The resulting intracellular proteolytic products
(CTF2 in the case of cadherins) contain the cytosolic domains of
the substrate proteins. Similar to the Notch intracellular domain,
some of these peptides may have a role as regulators of gene
expression [13]. Accordingly, work by Robakis and colleagues [10]
has demonstrated that soluble N-cadherin-CTF2 binds the tran-
scription factor CBP and promotes its degradation. Therefore, N-
cadherin-CTF2 functions as a repressor of CBP-dependent
transcription. Failed processing of PS1 and reduced cleavage of
substrates has been detected in FAD patients carrying PS1
mutations; these PS1 mutants are deficient in the processing of
Notch and N-cadherin [4,14,15]. It should be noted that PS1 is also
involved in Wnt/b-catenin signaling, acting as a negative modulator
of b-catenin?Tcf-4-mediated transcription [16–18]. b-catenin is a
multifunctional protein initially described as a mediator of cadherin-
dependent cell adhesion. In adherens junction complexes, b-catenin
is required for recruiting the actin cytoskeleton, a role that can also
be played by a related protein called plakoglobin or c-catenin.
Moreover, interaction of cadherins with p120-catenin that binds to a
distinct site is necessary for the stabilization of E-cadherin at the cell
membrane[19].Inadditiontoitsfunctionincelladhesion,b-catenin
is a central player in the Wnt pathway [20–22]. When released from
the junction complex, b-catenin translocates to the nucleus, where it
interacts with the Tcf-family of transcriptional factors and regulates
the expression of a variety of genes involved in embryonic
development and tumorigenesis [20,21]. For instance, it has been
shown that the activityof b-catenin?Tcf-4 isessential for maintaining
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and premature cell differentiation [23]. The translocation of b-
catenin to the nucleus is tightly controlled by the activity of a
complex involved in b-catenin degradation. This complex includes
the product of the tumor suppressor adenomatous polyposis gene,
axin, and the Thr/Ser protein kinases, CKIa and glycogen synthase
kinase 3b (GSK3b) [24]. As result of the activity of this complex, b-
catenin is phosphorylated and degraded by the proteasome. The
activity of the degradation complex is blocked by Wnt factors, which
stabilize cytosolic b-catenin [20,22]. Like b-catenin, plakoglobin also
interacts with Tcf-4, but in a sub-domain other than that binding b-
catenin. Since interaction of plakoglobin with Tcf-4 precludes
binding of Tcf-4 to DNA, plakoglobin works as a negative regulator
of the b-catenin-Tcf-4 complex [25–28].
In recent years, PS1 has been identified as an important negative
regulator of b-catenin signaling. Drosophila presenilin (DPS) works as
a negative modifier of wingless/Wnt in genetic screening [7] and
mutants deficient in DPS accumulate armadillo/b-catenin in the
cytoplasm [16]. Loss of PS1 in keratinocytes of knock-out mice
causeshighb-catenin-Tcf-mediatedsignaling,epidermalhyperplasia
and tumors [18]. Moreover, PS1 deficiency in primary fibroblasts
leads to increased activity of b-catenin target genes, including cyclin
D1[17]. However, the molecularbasisofthisinhibitoryeffectofPS1
on b-catenin-dependent transcription is controversial. According to
some authors, PS1 down-regulates b-catenin activity by enhancing
the stability of the E-cadherin-b-catenin complex [4], whereas other
authors have not detected this effect [29–31]. In a previous study we
reported that the inhibitory effect of non-processed presenilin
(npPS1) on b-catenin signaling in epithelial cells does not depend
on the proteolytic function of PS1 or the down-regulation of b-
catenin [32]. In these cell lines PS1 binds to plakoglobin and
enhances its interaction with Tcf-4, preventing Tcf-4 binding to
DNA. Here, we have further extended these studies using MEFs
deficient in the expression of PS1. Our data indicate that the
processed and unprocessed PS1 forms decrease b-catenin?Tcf-4-
dependent transcription through different mechanisms. Unlike
npPS1, the inhibitory effect of processed presenilin (pPS1) on b-
catenin activity is dependent on its c-secretase activity, and requires
binding of pPS1 to E- or N-cadherin and the subsequent cleavage of
the cytosolic domains of these cadherins, which in turn destabilize
the transcriptional cofactor CBP.
Materials and Methods
Preparation of DNA constructs
Full-length human PS1 and the point mutants M146L H163R,
C410Y and deleted in exon 9 (De9), kindly provided by Dr. C.A.
Saura (Institut de Neurocie `ncies, Universitat Auto `noma de
Barcelona, Spain) were cloned in pcDNA3.1 plasmid. Alterna-
tively, full-length PS1 was inserted in the BamHI-EcoRV sites of
pcDNA3.1MycA/His. The presence of the myc-tag at the C-
terminal end of wild-type PS1 impedes the endoproteolytic
processing of the protein. Full-length human CBP was cloned
into the BamHI-NotI site of pcDNA3.1-HA. Full-length cDNA of
murine E-cadherin was released from pBATEM2 plasmid by
digestion with BglII-HindIII and cloned into BglII-HindIII-
linearized pECFP-N1 vector. The DNA fragments corresponding
to the cytosolic domain of E-cadherin (E-cadh-CTF2, amino acids
732–883) or N-cadherin (N-cadh-CTF2, amino acids 746–906)
were amplified from murine RNA by RT-PCR using oligonucle-
otides corresponding to nucleotide sequences 2194–2219/2623–
2649 and 2235–2253/2699–2717, respectively. The 0.5 kilobase
amplification fragments were inserted in the BamHI-EcoRI site of
a pGEX-6P3 plasmid for E-cadherin, or in the BamHI-XhoI site
of a pGEX-6P1 plasmid for N-cadherin. To generate the
eukaryotic expression plasmid, the cytosolic cDNA fragments of
E- and N-cadherin were released from the pGEX-6P plasmid by
digestion with BamHI-EcoRI for E-cadherin and with BamHI-
XhoI for N-cadherin and cloned into BglII-EcoRI-linearized
pEGFP-C1 or BamHI-XhoI-linearized pcDNA3.1, respectively.
The preparation of the plasmids codifying for p120-catenin, Tcf-4
and b-catenin has been reported elsewhere [26,33,34].
Expression of recombinant proteins and pull-down
assays
GST-fusion proteins corresponding to the indicated forms of
p120-catenin and the cytoplasmic domains of E-cadherin (E-cadh-
CTF2) or N-cadherin (N-cadh-CTF2) were expressed in E. coli and
purified by affinity chromatography on glutathione-Sepharose [35].
When indicated, GST-cadh-CTF2 were phosphorylated in a final
volume of 50 ml of kinase buffer (9 mM MgCl2, 0.5 mM EGTA,
1 mM DTT, 0.5 mM EDTA, 28 mM a-glycerolphosphate pH 7.0,
0.1 mM ATP), using 22 pmols of GST-E-cadh-CTF2, GST-N-
cadh-CTF2 or GST as a control,and 300milliunits of proteinkinase
CKIa(Sigma).Reactionswereperformedfor40 minat30uC.When
required for the pull-down assays, GST was removed by cleaving
with Pre-Scission protease (Amersham Biosciences). Pull-down
assays were performed by using purified recombinant proteins fused
to GST and cell extracts from MEF PS (+/+) cells or deficient for
PS1 and PS2 (MEFs PS (2/2)), as described before [36].
Glutathione-Sepharose-bound proteins were analyzed by Western
blotting with specific monoclonal antibodies (mAbs) against p120-
catenin, b-catenin, E-cadherin, N-cadherin (all from BD Bioscienc-
es). The polyclonal antibody to the GST protein was from GE
Healthcare. PS1 was analyzed with a polyclonal antibody that
recognizes the full-length PS1 and the carboxyl-terminal PS1
fragment (Calbiochem). Serial immunoblots were performed after
stripping the membranes. All binding assays were repeated three
times. In order to quantify the amount of bound protein the
autoradiograms were scanned in a densitometer.
Transient cell transfections and analysis of protein
expression
The cell lines SW-480 and murine embryonic fibroblast wild
type (MEF PS (+/+)) or deficient for PS1 and PS2 (MEF PS (2/2))
were used in this study. MEF PS (2/2) were generously provided
by Dr. B. De Strooper [37,38]. SW-480 cells were established from
a primary colon adenocarcinoma and express a mutant form of
APC [39]. Cells were routinely grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum.
Transient expression of ectopic proteins was achieved in 80% of
the confluent cells with the indicated cDNAs inserted in eukaryotic
plasmid and using LipofectAMINE 2000 (Life Technologies)
according to the instructions of the manufacturer. Cells were
analyzed 24 or 48 hours after transfection. Total cell extracts were
prepared from culture cells resuspended in lysis buffer (25 mM
Tris-HCl, pH7.6, 150 mM NaCl, 1 mM EDTA, 1% digitonin),
supplemented with protease inhibitors (0.3 mM aprotinin, 0.1 mM
leupeptin, 1 mM pepstatin, 1 mM Pefabloc) and phosphatase
inhibitors (10 mM NaF, 0.1 mM sodium orthovanadate). After
passing cell homogenates 10 times by a insulin syringe, extracts
were left on ice for 15 min and centrifuged at 14.000 xg for 5 min
at 4uC. Supernatants constituted the whole cell extract.
Cell fractionation and immunoprecipitation
Cytosolic fractions were prepared by homogenizing cells in
RIPA buffer (25 mM Tris-HCl pH7.6, 200 mM NaCl, 1 mM
PS1 Effects on b-Catenin?Tcf-4
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40), supplemented with protease inhibitors and phosphatase
inhibitors. Cell homogenates were left on ice for 15 min and
centrifuged at 500 xg for 10 min at 4uC to obtain the cytosolic
fractions. Pellets were resuspended in the same volume of RIPA
buffer supplemented with protease and phosphatase inhibitors.
After passing cells 20 times by a insulin syringe, extracts were left
on ice for 15 min and centrifuged at 20.000 xg for 10 min at 4uC.
Supernatants constituted the nuclear fraction.
Proteins were immunoprecipitated from cell extracts (300 to
600 mg) by using 4 mg/ml of the appropriate antibody for 16 h
at 4uC. Precipitated material was removed by centrifugation at
12,000 xg and the resulting supernatant was incubated for
90 min with 30 ml of protein A-agarose (Sigma). Immunopre-
cipitates were washed three times with lysis buffer and bound
proteins directly eluted with electrophoresis sample buffer and
analyzed by Western blotting. When appropriate, mouse
TrueBlot reagent (BD Biosciences) was used as a secondary
antibody in order to eliminate interferences in the autoradio-
gram.
Luciferase reporter assays
Cells were transfected as above with the different promoters.
TOP-Flash plasmid, a synthetic promoter sensitive to the activity
of the b-catenin?Tcf-4 complex, that contains three copies of the
Tcf-4 binding site upstream of a firefly luciferase reporter gene
[40]. CRE-dependent transactivation was measured in the
presence of a CRE-luciferase reporter plasmid (pCRE-Luc)
(Oncogene), and NFkB-dependent transactivation was measured
with the NF3 plasmid, a NFkB-sensitive plasmid containing three
binding sequences for this transcriptional factor upstream a
luciferase reporter gene, provided by Dr. M. Fresno (Universidad
Auto ´noma de Madrid, Spain). PS1, CBP, E-cadh-CTF2, N-cadh-
CTF2, Tcf-4, p120-catenin or the indicated plasmids and controls
were cotransfected when indicated. Activity of the product of the
Renilla luciferase gene under the control of a constitutive thymidine
kinase promoter (Promega) was used as a control. Assays were
always performed in triplicate; the average of the results of three-
four independent transfections6S.D. is given.
Statistical analysis
Statistical analyses were carried out using SPSS software version
14. The results of the means percentage were compared by
ANOVA. P values of ,0.05 were considered to be significant in
each case.
Stable cell transfections and cell proliferation analysis
MEF PS (2/2) cells were cotransfected with 10.5 mg of either
pcDNA3.1-PS1 (pPS1), pcDNA3.1-Myc/His-PS1 (npPS1) or
empty vector and 1.5 mg pBABE-puro hrGFP. After 48 h,
transfected cells were selected with medium containing 2.5 mg/
ml Puromycin for additional 48 hours. Total cell protein extracts
were prepared as indicated above; RNAs were obtained as
previously reported [41] and analysed by quantitative RT-PCR
using the QuantiTect SYBR Green RT-PCR (Qiagen) in
triplicate using oligonucleotides specific for c-Fos (5’-TCCAG-
CATGGGCTCGC-3’, sense and 5’-GACCGTGGGAATGAA-
GTTGG-3’, antisense), c-Myc, Fibronectin or HPRT [41]. Cell
proliferation was determined counting every 24 h up to 96 h post-
seeding the number of cells in 20 different colonies of each
subpopulation. The proliferation rate of cells transfected with
pPS1 and npPS1 was expressed referred to the proliferation rate of
control cells in terms of percentage.
Results
We analyzed the effect of two different forms of PS1 on the
activity of TOP reporter plasmid, a widely used system to
determine b-catenin?Tcf-4 transcriptional activity. An untagged
form of PS1 was partially processed when transfected to epithelial
intestinal SW-480 cells (Figure 1A). However, a form of PS1
containing a myc tag in the C-terminus was not proteolysed
(Figure 1A) and remained as a 50 kDa protein, as previously
shown [42]. Both PS1 forms inhibited TOP activity, although
npPS1 did so to a greater extent than processed pPS1 (Figure 1B).
More importantly, the inhibition of TOP activity by both forms of
PS1 was differently regulated by the c-secretase inhibitor L-
685,458 [43]: whereas this compound did not affect the repression
by npPS1, it totally prevented the effect of pPS1 (Figure 1B).
Similar experiments were performed in murine embryo
fibroblasts (MEFs) obtained from PS1 and PS2 knock-out animals,
transfecting the two PS1 forms to levels similar to those detected in
control MEFs (+/+) (Figure 1C). The tagged PS1 (npPS1) was not
processed in these PS1 (2/2) cells at the two time points
analyzed. Conversely, wild-type PS1 was detected mainly as a
29 kDa band 24 hours after transfection and was totally processed
after 48 hours. We also determined the behavior of four PS1
mutants, initially described in FAD patients. Two of these
mutants, M146L and H163R, were processed although not as
efficiently as the wild-type form, since the predominant form at
24 hours was the 50 kDa uncleaved protein (Figure 1C). However
at 48 hours they were almost completely processed. On the other
hand, C410Y and De9 PS1 mutants remained as a 50 kDa band at
the two time points analyzed (Figure 1C).
The effect of all these PS1 forms on the TOP activity was also
determined. Although both the processed and non-processed forms
of PS1 inhibited this activity, the non-processed proteins (npPS1,
C410Y and De9) did it to a higher extent (Figure 1D). This
difference was more easily observed after 48 hours (Figure 1D,
lower panel), correlating with the more extensive processing of the
wild type, M146L and H163R PS1 forms. Moreover, the inhibition
of the TOP activity by the non-processed forms (thus, npPS1,
C410Y and De9 at 48 hours; all but the wild-type protein at
24 hours) was insensitive to the c-secretase inhibitor L-685,458,
whereas that of the processed forms (wild-type pPS1 or M146L and
H163R mutants) was prevented by this compound (Figure 1D). The
same sensitivity of TOP activity to L-685,458 was observed in wild-
type MEFs (+/+); addition of this compound also raised the activity
of this promoter in wild-type MEFs up to the values detected in
MEFs (2/2) (Figure 1D, lower panel).
Therefore, these results indicate that PS1 presents c-secretase-
dependent and -independent inhibitory effects on b-catenin?
Tcf-4-dependent transcription that are related to its own
processing.
Inhibition of b-catenin?Tcf-4 transcriptional activity by npPS1
is related to its ability to interact with plakoglobin [32]. Using pull-
down assays with GST-plakoglobin as bait, pPS1 showed lower
binding to this protein than npPS1 (Figure 2A). A quantification of
the association of both PS1 forms with GST-plakoglobin indicated
that npPS1 binds ten-fold better than pPS1 (Figure 2B). No
significant differences were observed in the association with GST-
plakoglobin for the different non-processed mutants used in
Figure 1, and the wild-type non-processed protein (Figure 2B).
The two processed PS1 mutants (M146L and H163R) presented a
similar binding to GST-plakoglobin than wild-type pPS1.
Analogous results were obtained when binding to b-catenin was
analyzed (not shown). These results suggest that pPS1 does not
affect b-catenin?Tcf-4 transcriptional activity through its binding
PS1 Effects on b-Catenin?Tcf-4
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forms act through different mechanisms.
We further investigated the mechanism involved in the
repression of b-catenin?Tcf-4 transcriptional activity by pPS1 in
MEFs. Deficiency of PS1 and PS2 caused increased levels of E-
cadherin, N-cadherin, plakoglobin and, to a lesser extent, b-
catenin (Figure 3A). The expression of another adherens junction-
associated protein, p120-catenin, was not altered. The differences
in the expression of these proteins were not due to different
transcription since their RNAs remained equal (not shown).
Addition of the c-secretase inhibitor L-685,458 reverted the levels
of these proteins (Figure 3B), suggesting that altered expression of
these proteins might be the origin of the repression of b-
catenin?Tcf-4 transcriptional activity.
It has been proposed that PS1 promotes the degradation of b-
catenin and, as a consequence of lower availability of this protein,
inhibits b-catenin translocation to the nucleus and its transcrip-
tional activity [44]. However, the decrease in b-catenin levels,
Figure 2. npPS1 shows a higher binding to plakoglobin than pPS1. (A) Pull-down assays were performed by incubating 10 pmols of GST-
plakoglobin or GST (as a control) with 500 mg of whole-cell extracts from MEFs PS (2/2) transfected with the indicated froms of PS1 inserted in
pcDNA3 plasmid. Protein complexes were affinity-purified with glutathione-Sepharose and analyzed by SDS-PAGE and Western blotting with anti-PS1
(aa 1–65) and anti-GST, to ensure that similar levels of fusion proteins were present in all cases. In the Input lane, a sample corresponding to 5% of the
total cell extracts used for the assay was loaded. (B) Western blots corresponding to three different experiments were scanned and quantified with
respect to the corresponding input. The panel shows the average (+/2 S.D.) of the binding calculated for the different PS1 forms.
doi:10.1371/journal.pone.0004080.g002
Figure 1. Processed and non-processed PS1 block b-catenin?Tcf-4-dependent transcription differently. SW-480 (A,) and MEF PS (2/2)
cells (C) were transfected with 5 mg of pcDNA3 plasmid containing either Myc/His-tagged PS1 (npPS1), wild-type PS1 (pPS1), the indicated mutants, or
empty vector as a control. After 48 hours (A) or at the indicated times (C), cell extracts were prepared as described in Materials and Methods.5 0mgo f
untransfected or transfected total cell extracts were analyzed by SDS-PAGE and Western blot with antibodies anti-PS1 (amino acids 1–65) and anti-b-
actin as a control (A and C). In panels B and D cells SW-480 and MEFs were cotransfected with 150 (+, in B) or 300 ng (++, in B; and D) of pcDNA-3
containing npPS1, pPS1, or, the indicated mutants, plus TOP-FLASH (50 ng) and pTK-Renilla (10 ng) luciferase plasmids. Relative luciferase activity was
determined with a dual luciferase reporter assay system 48 hours after transfection (B) or at the indicated times (D), and the result was normalized
using the Renilla luciferase activity for each sample. Percentage activity was calculated by comparing levels of luciferase activity with levels after
transfection of the empty plasmid alone. 5 mM c-secretase inhibitor L-685,458 (Calbiochem) was added to the medium for the last 24 h (panels B and
D). Values are the average +/2 S.D. of three-four experiments performed in triplicate. One asterisk (*) indicates p,0.05; two asterisks (**) p,0.01; in
the rest of the comparisons, the value of p is presented.
doi:10.1371/journal.pone.0004080.g001
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in the cytosol but not in the nucleus (Figure 3C). Moreover, in
both cell types the amount of b-catenin immunoprecipitated with
Tcf-4 was similar (Figure 3D), indicating that a mechanism other
than decreased expression of b-catenin is responsible for the effect
of processed PS1 on b-catenin-transcriptional activity in MEFs.
PS1-deficient MEFs showed higher levels of E- and N-cadherin
than wild-type MEFs. For both cadherins, full-length proteins and
C-terminal fragments, CTF1 (at 37 kDa for E-cadherin and 39 kDa
for N-cadherin) were detected at higher levels in MEFs (2/2)t h a n
in MEFs (+/+) (Figure 4A, lanes 1 and 2). However, MEFs (2/2)
lack the 35 kDa C-terminal fragments (CTF2) generated by the
action of c-secretase on CTF1 (Figure 4A). Addition of L-685,458
increased the amount of full-length and CTF1 E-cadherin in wild-
type MEFs and down-regulated the CTF2 fragment (Figure 4A,
compare lanes 2 and 3). A more detailed study of the stability of E-
cadherininMEFsdemonstrated that theabsenceofPSincreased the
half-life of this protein from 8 hours in wild-type MEFs to 24 hours
in PS-deficient cells (Figure 4B).
The destabilization of E-cadherin by PS1 was also observed
when both proteins were ectopically expressed in MEFs (2/2). As
shown in Figure 4C, the amount of ectopic CFP-E-cadherin,
detected as a 145 kDa band, was down-regulated by cotransfec-
tion with pPS1. Levels of E-cadherin were partially recovered by
addition of the c-secretase inhibitor. However, transfection of
npPS1 did not modify the stability of E-cadherin (Figure 4C).
The direct interaction of E-cadherin with the processed and
non-processed PS1 forms was also determined by pull-down
assays. As observed in Figure 5A (lanes 7 and 8), binding of pPS1
to the cytosolic fragment of E-cadherin was detected, either when
pPS1 was transfected or when the endogenous protein was present
in MEFs. However, npPS1 did not interact with E-cadherin,
although this form was expressed at higher levels than pPS1
(Figure 5A).
Figure 3. PS depletion increases protein levels of adherens junction-associated proteins. (A) 50 mg of MEF PS (2/2) and PS (+/+) total-cell
extracts were analyzed by Western blotting with the indicated antibodies. (B) MEF PS (+/+) cells were incubated with 1–5 mM c-secretase inhibitor L-
685,458 for 24 h. Then, total cell extracts were prepared as described in Experimental Procedures and analyzed by SDS-PAGE and Western blot with
the indicate antibodies. No effect of the c-secretase inhibitor was detected in PS/2/2) cells on the levels of the studied proteins (not shown). (C)
Cytosolic and nuclear fractions of MEF PS (2/2) and PS (+/+) cells were prepared as described. When indicated, MEF PS (+/+) cells were incubated
with 5 mM c-secretase inhibitor L-685,458 for 24 h. 50 mg of each fraction was analyzed by Western blotting with anti-b-catenin, anti-b-actin and anti-
laminB1. (D) 800 mg of MEF PS (2/2) and PS (+/+) total-cell extracts were immunoprecipitated with an anti-b-catenin MAb, and analyzed by Western
blot with specific antibodies against Tcf-4 and b-catenin. In the Input lane, a sample corresponding to 7% of the total cell extracts used for the assay
was loaded.
doi:10.1371/journal.pone.0004080.g003
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p120-catenin binding site [4]. Accordingly, interaction of pPS1
with E-cadherin competed with p120-catenin, since addition of
this recombinant protein decreased the amount of PS1 associated
with GST-E-cadh-CTF2 (Figure 5B). Moreover, transfection of
p120-catenin to MEF (2/2) cells stabilized the ectopically
expressed E-cadherin (CFP-E-cadherin, corresponding to the
145 kDa band) or the endogenous protein (corresponding to the
120 kDa band) and totally prevented the decrease in the levels of
these proteins caused by simultaneous expression of pPS1
(Figure 5C, compare lanes 3 and 5). As expected, p120-catenin
also inhibited the generation of E-cadherin CTF2 observed after
expression of pPS1 (Figure 5C).
Next, we checked the influence of p120-catenin on the effect of
PS1 on b-catenin?Tcf-4 transcriptional activity. Addition of p120-
catenin prevented the repression caused by pPS1 of TOP promoter
activity without affecting that caused by npPS1 (Figure 5D),
suggesting again that the generation of E-cadherin or N-cadherin
CTF2 is involved in the effect of pPS1, but not of npPS1, on b-
catenin?Tcf-4-dependent transcription. Accordingly, transfection of
E-cadh-CTF2 (Figure 5D) and N-cadh-CTF2 (not shown) inhibited
TOP promoter activity. As expected, repression by E-cadh-CTF2
was independent of p120-catenin (Figure 5D, bars 4 and 8).
Subcellular location of CTF2, determined transfecting this
protein tagged with GFP, indicated that this protein was detected
exclusively in the cytosol (data not shown). This result, and
previous observations shown in Figures 3C and 3D (pPS1 does not
prevent b-catenin translocation to the nucleus or binding to Tcf-4),
suggest that the effect of CTF2 is other than inhibition of b-catenin
binding to Tcf-4.
N-cadherin CTF2 is involved in the down-regulation of CBP
[10], a transcriptional coactivator required for b-catenin tran-
scriptional activity. CBP expression was higher in PS-deficient
MEFs than in the normal counterpart cells (Figure 6A). However,
the levels of another transcriptional factor of this family, pCAF,
were not altered. Addition of L-685,458 raised CBP in wild-type
MEFs up to levels similar to those detected in MEFs (2/2)
(Figures 6A and 6B). Although mostly nuclear, CBP was also
detected in the cytosol in lower amounts (Figure 6B), where E-
cadh-CTF2 was also present.
Figure 4. pPS1, and not npPS1, is responsible for down-regulation of E-cadherin levels. (A) MEF PS (+/+) cells were incubated with 5 mM
c-secretase inhibitor L-685,458 for 24 h. 50 mg of MEFs PS (2/2) and PS (+/+) total cell extracts were analyzed by SDS-PAGE and Western blot with the
indicated antibodies. (B) MEF PS (2/2) and PS (+/+) cells were incubated with 25 mg/ml cycloheximide for the indicated time periods. 10 mg of MEF
PS (2/2) and 60 mg of MEF PS (+/+) total cell extracts were analyzed by Western blot with anti-E-cadherin, anti-PS1 (N-terminus) and anti-b-actin-
specific antibodies. Autoradiograms were scanned; the values obtained for E-cadherin were referred to the initial time. (C) MEF PS (2/2) cells were
cotransfected with 2.5 mg of pECFPN1-E-cadherin and 2.5 mg of pcDNA3.1-Myc/His-PS1 (npPS1) or pcDNA3.1-PS1 (pPS1) plasmids. 24 h after
transfection, 5 mM c-secretase inhibitor L-685,458 was added to the medium for 24 h. Percentage of transfection was estimated to be approximately
80%, determining the number of CFP-positive cells. 50 mg of total cell extracts were analyzed by Western blotting with the indicated antibodies. At
the right, the ectopic E-cadherin levels of three different experiments were quantified and represented with respect to control (no expression of
either pPS1 or npPS1). Values are the average +/2 S.D. of these experiments.
doi:10.1371/journal.pone.0004080.g004
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of b-catenin?Tcf-4-dependent transcription caused by expression
of pPS1 in MEFs (2/2) (Figure 6C) and stimulated this parameter
in MEFs (+/+). On the other hand, expression of CBP did not
prevent the inhibition of TOP activity caused by npPS1
(Figure 6C). A similar effect was observed when the repression
of TOP promoter by E- or N-cadherin CTF2 was analyzed: the
effect of both cadherin fragments was prevented by CBP over-
expression (Figure 6D).
Down-regulation of CBP levels by N-cadherin-CTF2 has been
reported to be dependent on their interaction [10]. Association of
CBP was detected not only with N-cadherin CTF2 but with E-
cadherin CTF2. Fusion proteins containing E-cadherin or N-
cadherin CTF2 showed similar binding to CBP (Figure 7A).
Phosphorylation of CTF2 by CK1, a protein kinase active on this
fragment [45], consistently decreased the association of CBP with
CTF2, raising the possibility that this interaction might be
modulated in vivo. The interaction was also detected by co-
immunoprecipitation using cytosolic fractions and a previous
treatment with proteasome inhibitors such as MG132, in order to
prevent the degradation of CBP. As shown in Figure 7B (lane 2), in
extracts treated with MG132, transfection of E-cadherin CTF2
induced the appearance of high molecular weight forms of CBP,
presumably corresponding to ubiquitinated variants of this factor.
The presence of CTF-2 was detected in CBP immunoprecipitates,
further demonstrating the association between these two proteins
(Figure 7B).
We also analyzed several different properties of the transcrip-
tional repression by processed and non-processed PS1. Since
npPS1 affects b-catenin?Tcf-4 transcriptional activity by seques-
Figure 5. p120-catenin prevents the interaction of pPS1 with E-cadherin, the generation of E-cadherin-CTF2 fragment and the
inhibition of b-catenin?Tcf-4 transcriptional activity. (A) MEF PS (2/2) cells were transfected with npPS1 or pPS1: pcDNA3.1-Myc/His-PS1
(npPS1) or pcDNA3.1-PS1 (pPS1). After 48 h total cell extracts were prepared and incubated with 15 pmols of GST-E-cadh/CTF2 or GST as a control;
cell extracts from MEFs PS (+/+) were also incubated. Protein complexes were purified with glutathione-Sepharose and associated PS1 was analyzed
by Western blotting with a specific antibody against PS1 (C-terminus). Blots were re-analyzed with anti-GST to ensure that similar levels of fusion
protein forms were present in all samples. In the Input lane, a sample containing 5% of the total cell extracts used for the assay was loaded. (B) 12
pmol of GST-E-cadh-CTF2 or GST as a control were pre-incubated with 20 pmols of p120-catenin and pulldown assays performed as above with 1 mg
of MEF PS (+/+) total cell extracts. (C) MEF PS (2/2) cells were cotransfected with 2.5 mg of pECFPN1-E-cadherin and pcDNA3.1-PS1 (pPS1) or
pcDNA3.1-p120-catenin. 50 mg of total cell extracts were analyzed by SDS-PAGE and Western blot with the indicated antibodies. At the right, the
ectopic E-cadherin levels of three different experiments were quantified and represented with respect to control (no additions). Values are the
average +/2 S.D of these experiments. (D) MEF PS1(2/2) cells were cotransfected with pcDNA3.1-PS1 (pPS1), pcDNA3.1-Myc/His-PS1 (npPS1),
pcEGFPC1-E-cadh-CTF2, pcDNA3.1-p120-catenin or empty vector (150 ng), TOP-FLASH (50 ng) and pTK-Renilla (10 ng) luciferase plasmids. MEF
PS1(+/+) cells were transfected with pcDNA3.1-p120-catenin or empty vector (150 ng). Relative luciferase activity was determined with a dual
luciferase reporter assay system 48 h after transfection, and the result was normalized using the Renilla luciferase activity for each sample. Percentage
activity was calculated by comparing levels of luciferase activity with levels after transfection of the empty plasmid alone. Values are the average +/2
S.D. of three-four experiments performed in triplicate. 2, absent; +, present. (*) indicates p,0.05; (**), p,0.01; in the rest of the comparisons, the p
value is shown. NS, not significant.
doi:10.1371/journal.pone.0004080.g005
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form is prevented by Tcf-4 over-expression [32]. These results
were reproduced in MEFs (2/2) (Figure 8A, lanes 7–9).
However, neither pPS1 nor E-cadherin CTF2 inhibition of TOP
activity were significantly affected by Tcf-4 (Figure 9A, lanes 4–6
for pPS1, and 10–12 for CTF2). According to these results, the
repression of TOP activity by the non-processed PS1 mutants
(C410Y or De9), but not by the processed forms (H163R and
M146L), was also prevented by over-expression of Tcf-4 (data not
shown).
Since pPS1 decreases the cell levels of CBP, we expected that it
not only affects the activity of b-catenin?Tcf-4 complex but also
that of other transcriptional factors dependent on this cofactor,
such as CREB (cyclic AMP response-element binding protein).
Binding of CBP is required for stimulation by CREB of the
expression of genes containing CREs (cyclic AMP responsive
elements) in their promoters. Therefore, we checked the effects of
both PS1 forms on the activity of a CRE luciferase reporter
plasmid in cells stimulated with forskolin. Whereas npPS1 did not
affect the activity of this promoter, pPS1 repressed it by 50%
(Figure 8B). As expected, expression of CBP reversed the
inhibition of CRE activity by pPS1. Activity of this promoter
was also significantly lower in wild-type MEFs than in PS-deficient
cells and was recovered by CBP expression (Figure 8B).
CBP also modulates the activity of NF-kB [46]. Activity of an
NF-kB-reporter plasmid was also sensitive to the expression of
pPS1, E-cadherin or N-cadherin CTF2, but not to npPS1
(Figure 8C). Mimicking the results obtained with TOP or CRE
reporters, co-expression of CBP abolished the inhibition by these
three factors. Activity of this promoter was lower in wild-type
MEFs than in mutant cells and was increased, although not
statistically significantly, by CBP expression.
Finally, we analyzed the effect of the two PS1 forms on gene
expression in stable MEFs transfectants. Both forms differently
Figure 6. CBP prevents the repression of b-catenin?Tcf-4 transcriptional activity caused by the expression of pPS1, E- or N-cadherin
CTF2. (A) MEF PS (+/+) cells were incubated with 5 mM c-secretase inhibitor L-685,458 for 24 h. 50 mg of MEFs PS (2/2) and PS (+/+) total cell extracts
were analyzed by SDS-PAGE and Western blot with anti-CBP and anti-b-actin antibodies. Autoradiograms were scanned and the average level of CBP
obtained in the three different experimental conditions is represented in the right panel. Values correspond to the average +/2 S.D of four
experiments. (B) Cytosolic and nuclear-associated fractions of MEF PS (2/2) and PS (+/+) cells (incubated with 5 mM c-secretase inhibitor L-685,458)
were prepared as detailed in Experimental Procedures.5 0mg of each fraction was analyzed by SDS-PAGE and Western blot with the indicated
antibodies. (C) MEF PS (2/2) cells were cotransfected with either pcDNA3.1-PS1 (pPS1) or pcDNA3.1-Myc/His-PS1 (npPS1) and pcDNA3.1-HA-CBP and
(D) with pcEGFPC1-E-cadh-CTF2 or pcDNA3.1-N-cadh-CTF2 or empty vector (150–300 ng), TOP-FLASH (50 ng) and pTK-Renilla (10 ng) luciferase
plasmids. Relative luciferase activity was determined with a dual luciferase reporter assay system 48 h after transfection, and the result was
normalized using the Renilla luciferase activity for each sample. Percentage activity was calculated by comparing levels of luciferase activity with
levels after transfection of the empty plasmid alone. Values are the average +/2 S.D. of three-four experiments performed in triplicate. (*) indicates
p,0.05; (**), p,0.01; in the rest of the comparisons, the p value is shown. NS, not significant.
doi:10.1371/journal.pone.0004080.g006
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npPS1 proliferated at a rate 38% of control cells, those expressing
pPS1 did it at a 60% (Figure 9A). Since c-myc is a well-established
target of b-catenin?Tcf-4 transcriptional activity [23,47], we
analyzed whether processed and non-processed PS1 forms
similarly inhibited the expression of this protein. As shown in
Figure 9A, npPS1 greatly decreased the expression of c-myc,
whereas pPS1 barely affected it.
The effect of both PS1 forms on c-Fos RNA was also examined,
since expression of this gene has been reported to be sensitive to
CREB, pPS1 and the c-secretase inhibitor L-685,458 [10]. As
shown in Figure 9B, pPS1 transfectants contain lower levels of c-
Fos RNA than control populations; however expression of npPS1
did not substantially modify this RNA. The effect on c-myc RNA
was the opposite, in agreement with the results of c-myc protein
analysis: npPS1 substantially decreased c-myc RNA whereas pPS1
did not (Figure 9B). Similar effects were obtained on Fibronectin
RNA, another target of b-catenin [48], although in this case the
repression caused by npPS1 was smaller (Figure 9B).
Therefore these results indicate that processed and non-
processed PS1 act differently on gene transcription.
Discussion
In recent years, a growing amount of evidence has indicated
that PS1 controls the transcriptional activity of the b-catenin?Tcf-4
complex. Different mechanisms have been put forward, involving
the interaction of PS1 with N- and E-cadherin and b-catenin and
the activity of the c-secretase complex [4,5,49–51]. We previously
studied the effect of a non-processed form of PS1 on b-
catenin?Tcf-4 transcription in epithelial cells. In this study, we
have extended our analysis to MEFs and compared the effects of
processed and non-processed forms of PS1. Ours results indicated
that, differently to pPS1, npPS1 has high affinity for b-catenin and
for plakoglobin, a protein that is very similar to b-catenin.
Moreover, npPS1 potentiates the association of plakoglobin and b-
catenin with Tcf-4 and prevents the interaction of the ternary
complex PS1-plakoglobin-Tcf-4 with DNA [32]. All these effects
do not require the c-secretase activity, since they are not prevented
by L-685,458, a widely used inhibitor of this activity.
When processed, PS1 affects b-catenin?Tcf-4 transcription
through a completely different mechanism, in this case dependent
on its c-secretase activity. Unlike npPS1, pPS1 has a detectable
association with E or N-cadherin and facilitates the generation of a
C-terminal fragment of both proteins consisting of the cytosolic
domain (CTF2). It is not yet known whether the interaction of PS1
withcadherinsisdirectormediatedbyothermembranecomponents
since the binding experiments have not been performed using pure
proteins. Therefore, the lack of interaction of npPS1 with cadherins
may be due to its inability to associate with the factor mediating this
interaction, maybe because of a hampered localization of npPS1 in
the cytoplasmic membrane. This lack of interaction with cadherins
might be a more general property of mutant PS1 forms, since many
of these mutants show defects in their cell trafficking and,
presumably, are not located in the cell membrane [14,52]. At this
respect, it has been recently shown that interaction of pPS1 with N-
cadherin and its localization in the plasma membrane is negatively
controlled by GSK3b [53]. However, the lack of association of
npPS1 with E-cadherin detected in pull-down assays suggests that
some intrinsic properties of the non-processed proteins hinder its
interaction with the cadherins, either directly or indirectly. In any
case, it is possible that the different association of PS1 forms with
cadherins has physiological relevance, since binding of pPS1 to N-
cadherin facilitates the recruitment of PI3 kinase (PI3K) and the
activation of the PI3K/Akt survival pathway [54]. The absence of
association of npPS1 with N-cadherin and the lack of activation of
this pathway might be responsible for the neurodegeneration
observed in cells bearing a mutation that prevents processing
It should be noted that pPS1 affects the stability of E- and N-
cadherin, although c-secretase does not participate in the processing
Figure7.The CTF2fragment ofE-cadherin interacts withCBP. (A)
GST-E-cadh-CTF2 and GST-N-cadh-CTF2 were phosphorylated with CKId,
as described in Material and Methods. 20 pmols of non-phosphorylated or
phosphorylated GST-cadh-CTF2 proteins, or GST as a control, were
incubated with 1.2 mg of MEF PS (2/2) total cell extracts. Protein
complexes were affinity-purified with glutathione-Sepharose and ana-
lyzed by SDS-PAGE and Western blotting with anti-CBP and anti-GST, to
ensurethatsimilarlevelsoffusionproteinswerepresentinallcases.Inthe
Input lane,asamplecorrespondingto5%ofthetotalcellextractsusedfor
the assay was loaded. Autoradiograms were scanned and the average of
CBP bound with respect to the value obtained without CKI is shown
below the western blot (average +/2 S.D. of three experiments). (B) MEFs
PS (2/2) were transfected with 7 mg of GFP or E-cadh-CTF2-GFP, to
simulate the CTF2 fragment present in MEF PS1/PS2 (+/+). After 24 h
expression, cells were treated with the proteosome inhibitor MG132 at 30
mMfor4h.RIPAbufferwasusedtoobtaincytosoliccellfraction.FortheIP,
500 mg of the cytosolic fraction were incubated with 2.5 mgo fa n t iC B P
antibody to a final lysate concentration of 1 mg/ml. 30 mg of cytosolic cell
lysates were loaded for inputs.
doi:10.1371/journal.pone.0004080.g007
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binding competes with that of p120-catenin, it is possible that pPS1
prevents the stabilization caused by this catenin on E-cadherin [55]
or, alternatively, potentiates the initial processing of E-cadherin,
perhaps facilitating the binding of the responsible protease.
The effect of pPS1 on E-cadherin stability is also demonstrated by
the remarkable levels of expression of this protein in MEFs deficient
for PS1. Actually these cells present a more epithelioid phenotype
than wild type MEFs (data not shown). This unexpected result
suggests that in these fibroblasts E-cadherin expression is not
exclusively modulated at the transcriptional level, as it is generally
considered [56]. At this regard, MEFs present lower expression of
theE-cadherinrepressorSnail1(Snail)[56]thanculturedfibroblastic
cell lines (I.R., A.G.H. and M.D., unpublished observations). Snail1
mRNA is not significantly different in PS1(2/2)M E F sw i t hr e s p e c t
to wild type MEFs, suggesting that down-regulation of this
transcriptional repressor does not contribute to the increased levels
of E-cadherin expression detected in PS1-deficient MEFs. It is also
likely that up-regulated E-cadherin affects the levels of other
associated proteins, such as b-catenin and plakoglobin, inhibiting
their degradation.
Unlike what happens with E-cadherin, npPS1 associates with b-
catenin or plakoglobin much better than pPS1. It has been reported
that binding ofPS1tob-cateninwouldbedirectthrough the298–380
hydrophilic loop [57,58]. Since processing of PS1 occurs through the
cleavage of a peptidic bond present in this loop, it is likely that it
affects the interaction with b-catenin and plakoglobin. This could
explain the contradictory results obtained by many authors regarding
the interaction of PS1 and b-catenin, an association reported to be
either direct or dependent on E-cadherin [4,51].
Our results totally agree with previous reports indicating that
inhibition b-catenin transcriptional activity by pPS1 is dependent
on c-secretase-dependent generation of N-cadherin CTF2, a
fragment that induce the destabilization of the transcriptional
coactivator CBP [10]. We have extended this conclusion to E-
cadherin CTF2, also capable to bind and down-regulate CBP. On
the contrary, at least in MEFs (this report) and several epithelial
cell lines (not shown), npPS1 does not promote the generation of
E- or N-cadherin CTF2. Therefore, npPS1 selectively affects the
transcriptional activity of b-catenin?Tcf-4 complex, not affecting
other transcriptional factors that also recruit CBP. Consequently,
according to our model, mutations in PS1 that prevent processing,
such as those shown in Figure 1, C410Y and De9, will decrease the
activity of the b-catenin?Tcf-4 complex but will not affect, or even
up-regulate, other pathways involving CBP, such as those related
to CREB, NF-kB or p53 [10,59,60]. The effect of npPS1 on b-
catenin?Tcf-4 transcriptional activity would be more general than
that of pPS1, since the latter will be limited to the transcriptional
targets sensitive to CBP. Therefore, this unbalanced transcrip-
tional activity might be contributing to neurodegeneration in
Figure 8. Transcriptional repression by npPS1 and pPS1 has
different selectivity and requirements. (A) MEF PS (2/2) cells
were cotransfected with pcDNA3.1-Tcf-4 (150 and 300 ng), pcDNA3.1-
PS1 (pPS1), pcDNA3.1-Myc/His-PS1 (npPS1), pcEGFPC1-E-cadh-CTF2 or
empty vector (150 ng), TOP-FLASH (50 ng) and pTK-Renilla (10 ng)
luciferase plasmids. (B and C) MEF cells were cotransfected with 250 ng
of pcDNA3.1-PS1 (pPS1), pcDNA3.1-Myc/His-PS1 (npPS1), pcEGFPC1-E-
cadh-CTF2, pcDNA3.1-N-cadh-CTF2, pcDNA3.1HA-CBP or empty vector,
and pCRE-luc (60 ng) (panel B) or NF-kB-dependent promoter (50 ng)
(panel C) and pTK-Renilla (10 ng) luciferase plasmids. Relative luciferase
activity was determined with a dual luciferase reporter assay system
48 h after transfection, and the result was normalized using the Renilla
luciferase activity for each sample. Percentage activity was calculated by
comparing levels of luciferase activity with levels after transfection of
the empty plasmid alone. Values are the average +/2 S.D. of three-four
experiments performed in triplicate. (*) indicates p,0.05; (**), p,0.01;
in the rest of the comparisons, the p value is shown. NS, not significant
(p.0.05).
doi:10.1371/journal.pone.0004080.g008
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CTF2 but still capable of being processed, may behave less
severely than those deficient in processing, since their effect on b-
catenin?Tcf-4 transcription would be less robust. Although this
model is based on data obtained in cell lines, and should be
verified using a more physiological context, as knock-in mouse
animal models [61,62], we consider that it proposes an attractive
possibility worthy to be investigated.
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